This is a StreetInsider.com Premium Only Page

Kadmon (KDMN) – StreetInsider.com Reports

Oct 21, 2021 06:21 AM Kadmon (KDMN) Reports Expiration of HSR Waiting Period

Sep 14, 2021 02:17 AM Mizuho Securities Downgrades Kadmon Holdings (KDMN) to Neutral

Sep 9, 2021 04:12 AM Increasing unusual option volume: KDMN ATER VIH GSAT PVH

Sep 9, 2021 03:12 AM Jefferies Downgrades Kadmon Holdings (KDMN) to Hold

Sep 8, 2021 02:52 PM Raymond James Downgrades Kadmon Holdings (KDMN) to Market Perform, Following Acquisition

Sep 8, 2021 09:58 AM Increasing unusual option volume: KDMN VIH SMAR SOAC WIMI

Sep 8, 2021 09:20 AM Pre-Open Stock Movers 09/08: (KDMN) (GANX) (ADMA) Higher; (COTY) (PATH) (IMPL) Lower (more...)

Sep 8, 2021 06:05 AM Kadmon (KDMN) Acquired by Sanofi (SNY) for $9.50/sh or $1.9B

Aug 24, 2021 04:26 AM Increasing unusual option volume: TRIL BEKE KDMN PAGS FBRX AAP

Aug 9, 2021 04:55 AM Increasing unusual option volume: IHRT KDMN BNS CM RAMP TSP

Aug 6, 2021 09:55 AM Increasing unusual call option volume: KDMN IWN ETON ROST SD BTBT

Jul 20, 2021 09:41 AM Increasing unusual call option volume: ARDX SHCR HUM KDMN

Jul 19, 2021 02:48 PM Kadmon Holdings (KDMN) PT Raised to $10 at Jefferies, Following Clinical Business Update

Jul 19, 2021 09:22 AM UPDATE: Kadmon Holdings (KDMN) PT Raised to $9 at Oppenheimer on Early Approval of Rezurock

Jul 19, 2021 07:07 AM Kadmon (KDMN) Announces Pivotal Trial Data Published in the Journal Blood for REZUROCK (Belumosudil) in Chronic Graft-Versus-Host Disease

Jul 19, 2021 03:02 AM Increasing unusual option volume: KDMN IGT DOYU YVR SGH ENDP FGEN

Jul 16, 2021 02:37 PM Kadmon (KDMN) to Resume Trading at 2:45 p.m.

Jul 16, 2021 02:22 PM Kadmon (KDMN) Announces U.S. FDA Grants Full Approval of REZUROCK (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease

Jul 16, 2021 02:08 PM Kadmon (KDMN) Halted, News Pending

May 20, 2021 04:25 PM UPDATE: UBS Starts Kadmon Holdings (KDMN) at Buy

Apr 21, 2021 08:01 AM Kadmon (KDMN) Announces Publication of Phase 2a Clinical Trial Results of Belumosudil for cGVHD in the Journal of Clinical Oncology

Apr 1, 2021 08:05 AM Kadmon (KDMN) Reports First Patient Dosing in Open-Label Phase 2 Clinical Trial of Belumosudil in Systemic Sclerosis

Mar 11, 2021 09:28 AM Pre-Open Stock Movers 03/11: (SIEB) (VIR) (RBLX) Higher; (ALTO) (SUMO) (ORCL) Lower (more...)

Mar 10, 2021 05:39 PM After-Hours Stock Movers 03/10: (SIEB) (AVEO) (AMC) Higher; (ALTO) (CLDR) (KDMN) Lower (more...)

Mar 10, 2021 04:16 PM Kadmon (KDMN) Announces U.S. FDA Has Extended the Review Period for Belumosudil in Chronic Graft-Versus-Host Disease

Mar 5, 2021 07:26 AM Kadmon Holdings (KDMN) PT Raised to $10 at Raymond James

Mar 1, 2021 08:09 AM Kadmon (KDMN) Announces Appointment of Dr. Simon Cooper as Chief Medical Officer

Feb 11, 2021 09:24 AM Pre-Open Stock Movers 02/11: (ACIU) (MVIX) (DMTK) Higher; (FLDM) (ELY) (TLRY) Lower (more...)

Feb 10, 2021 05:54 PM After-Hours Stock Movers 02/10: (MVIS) (DMTK) (RNWK) Higher; (FLDM) (ELY) (KDMN) Lower (more...)

Feb 10, 2021 04:45 PM Kadmon (KDMN) Announces Proposed $150 Million Convertible Senior Notes Offering with Capped Call Transactions

Feb 10, 2021 09:04 AM Kadmon Holdings (KDMN) Survey Handicaps Belumosudil Market Share - Jefferies

Feb 1, 2021 08:10 AM Kadmon (KDMN) Announces Publication of Preclinical Data Demonstrating Anti-PD-L1/IL-15 Fusion Protein KD033 Achieves Robust Anti-Tumor Response

Dec 1, 2020 06:39 AM Kadmon Holdings (KDMN) Belumosudil Accepted for Priority Review, Oppenheimer Sees ASH as Next Catalyst

Nov 30, 2020 08:08 AM Kadmon (KDMN) Reports FDA Acceptance of NDA for Belumosudil in Patients With Chronic Graft-Versus-Host Disease

Nov 11, 2020 09:29 AM Pre-Open Stock Movers 11/11: (FPRX) (FUBO) (SURF) Higher; (EGAN) (ACB) (MODN) Lower (more...)

Nov 10, 2020 06:01 PM After-Hours Movers 11/10: (FPRX) (FUBO) (BRKS) Higher; (EGAN) (MODN) (LYFT) Lower (more...)

Nov 10, 2020 04:06 PM Mizuho Securities Starts Kadmon Holdings (KDMN) at Buy

Nov 6, 2020 01:40 PM Kadmon Holdings (KDMN) PT Lowered to $9 at Raymond James

Sep 30, 2020 04:20 PM Kadmon (KDMN) Reports Submission of NDA to FDA for Belumosudil in Patients with Chronic Graft-Versus-Host Disease

Sep 4, 2020 03:01 PM Kadmon's (KDMN) Treatment of Systemic Sclerosis Granted Orphan Status

Aug 17, 2020 06:43 AM Loeb's Third Point LLC Enters Gaming Names Activision (ATVI) and Take-Two (TTWO), China Plays Alibaba (BABA) JD (JD), Among Others - 13F

Aug 13, 2020 04:50 PM Kadmon (KDMN) Adds Nancy Miller-Rich to Board

Aug 7, 2020 08:17 AM Kadmon Holdings (KDMN) PT Raised to $10 at Raymond James

Jun 23, 2020 08:02 AM Kadmon (KDMN) Reports First Patient Dosing in Phase 1 Clinical Trial of KD033

Jun 5, 2020 04:17 PM Kadmon (KDMN) Raises $50 Million in Gross Proceeds Through Its at-the-Market Facility

May 21, 2020 12:44 PM Kadmon Holdings (KDMN) PT Raised to $9 at Raymond James

May 21, 2020 09:27 AM Pre-Open Stock Movers 05/21: (ACB) (KDMN) (TJX) Higher; (SCPH) (RUTH) (FLXN) Lower (more...)

May 21, 2020 07:27 AM Kadmon (KDMN) Announces Positive Topline Results of Pivotal Trial of Belumosudil (KD025) in cGVHD

May 19, 2020 06:52 AM Raymond James Starts Kadmon Holdings (KDMN) at Outperform

Apr 14, 2020 08:14 AM Kadmon (KDMN) Receives Final Meeting Minutes from FDA Following Pre-NDA Meeting for KD025 for Treatment of cGVHD, on Track for NDA Submission in Q4